Impact of ICCAN on Cancer Treatment Completion and Quality of Life

Recruiting

Interventions: Behavioral: The Integrated Cancer Care Access Network (ICCAN)
Behavioral: Usual and Customary Group (U&C)

Brief Summary: The purpose of this 1 year study is to see if the ICCAN program is working, and to compare the ICCAN program to the standard hospital services provided in New York City hospitals, like meeting with a Social Worker or a Patient Navigator (a person who provides personal hospital guidance).

Recruitment & Eligibility

Inclusion Criteria

Patient is eligible if he/she is

fluent in English, Spanish, or Mandarin
between the ages of 21-80 years old
cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or
scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)
planning on remaining in the area for at least 1 year

Clinician is eligible if he/she:

ICCAN-IO Phase 1: Refinement, participant is eligible if he/she per EMR or self-report:

Is 18 - 85 years of age
Has unresectable locally advanced, locally recurrent unresectable, metastatic, or high risk/early stage TNBC or stage I-IV lung cancer
Eligible for FDA approved immunotherapy in the NYC metropolitan area (per self-report or per MSK patient EMR records).
Is treated in the NY metropolitan area
Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined as household income < 200% of federal poverty level)
Has English or Spanish proficiency
Agrees to be audio-recorded

ICCAN-IO Phase 2: Pilot RCT, participant is eligible if he/she per EMR or self-report:

Is 18 - 85 years of age
Has stage II-III TNBC
Treated at MSK Manhattan or OneMSK regional sites
Self identifies as Black or Hispanic, and/or is low SES (low SES will be defined as household income < 200% of federal poverty level)
Has English or Spanish proficiency
Agrees to be audio-recorded

ICCAN-IO process evaluation study team participants only:

Participant

Exclusion Criteria

Patient is ineligible is he/she is:

Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent

ICCAN-IO Phase 1: Refinement, participant is ineligible if he/she per EMR or self-report:

Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
Participants or family members who are participating in MSK IHCD studies related to social determinants of health

ICCAN-IO Phase 2: Pilot RCT, participant is ineligible if he/she per EMR or self-report:

Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
Participants or family members who are participating in MSK IHCD studies related to social determinants of health

Arm && Interventions

Group	Intervention	Description
Phase I: Refinement	The Integrated Cancer Care Access Network (ICCAN)	10 Black, Hispanic, and/or low-SES patients with TNBC (5 Spanish-speaking), will be recruited from MSK
Phase II, Arm 1: Usual and Customary Care (U&C)	Usual and Customary Group (U&C)	Participants in this group will receive the same referrals on social and economic resources as ICCAN group.
Phase II, Arm 2: ICCAN-IO	The Integrated Cancer Care Access Network (ICCAN)	Arm 2 will consist of everything in Arm 1

Primary Outcome Measures

Name	Time	Method
Treatment completion/adherence	1 year	The primary outcome, cancer treatment completion, will be determined by chart review at 3, 6, and 12 months after enrollment.

Secondary Outcome Measures

Name	Time	Method
Quality of life	1 year	depression, and stress (measured through validated scales included in the Cancer Treatment Outcomes

Locations (11): Memorial Sloan Kettering Bergen (Limited Protocol Activities)
🇺🇸
Montvale, New Jersey, United States
Lincoln Hospital and Mental Health Center
🇺🇸
Bronx, New York, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
🇺🇸
Rockville Centre, New York, United States
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
🇺🇸
Commack, New York, United States
City College of New York (Data Collection AND Data Analysis)
🇺🇸
New York, New York, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
🇺🇸
Basking Ridge, New Jersey, United States
Lutheran Medical Center
🇺🇸
Brooklyn, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸
New York, New York, United States
Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)
🇺🇸
New York, New York, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
🇺🇸
Middletown, New Jersey, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
🇺🇸
Harrison, New York, United States